Table 2.
Pro12Ala genotype by participant characteristics for the subset of individuals in whom CT scans were undertaken
| Baseline characteristic | Pro12Pro (n=608) | Ala12X (n=117) | p value |
|---|---|---|---|
| Treatment | |||
| Placebo | 202 (86.7) | 31 (13.3) | 0.07a |
| Metformin | 198 (79.5) | 51 (20.5) | |
| Lifestyle | 208 (85.6) | 35 (14.4) | |
| Self-reported ethnicity | |||
| European American | 330 (79.7) | 84 (20.3) | <0.001b,a |
| African American | 147 (N/A) | N/Ac | |
| Hispanic | 105 (84.7) | 19 (15.3) | |
| Asian/Pacific Islander | 24 (N/A) | N/Ac | |
| American Indian | N/Ac | N/Ac | |
| Sex | |||
| Male | 203 (33.4) | 43 (36.8) | 0.48 |
| Female | 405 (66.6) | 74 (63.2) | |
| Age (years) | 51.8±10.4 | 53.0±10.9 | 0.24 |
| Weight (kg) | 90.9±17.1 | 92.4±16.2 | 0.40 |
| BMI kg/m2 | 32.6±5.6 | 33.1±5.1 | 0.36 |
| Waist circumference (cm) | 102±12.8 | 104±12.4 | 0.25 |
| SAT L 2/3 (cm2) | 294±117 | 308±116 | 0.25 |
| SAT L 4/5 (cm2) | 428±146 | 444±140 | 0.27 |
| VAT L 2/3 (cm2) | 193±84.5 | 215±92.7 | 0.01 |
| VAT L 4/5 (cm2) | 156±61.9 | 164±72.0 | 0.21 |
| PUFA (g/day) | 13.4 (2.6, 48.7) | 14.0 (3.2, 37.5) | 0.42d |
| Energy from PUFA (%) | 6.4 (3.0,14.0) | 6.3 (2.6, 11.6) | 0.44d |
| SFA (g/day) | 18.6 (3.1, 94.5) | 19.8 (6.6, 70.8) | 0.41d |
| Energy from SFA (%) | 11.5(3.7, 29.2) | 11.6 (2.8, 20.8) | 0.45d |
| PUFA: SFA ratio | 0.71 (0.17, 4.85) | 0.69 (0.16, 2.92) | 0.76d |
Data are n (percent), mean±SD or median (min, max). Genotype percentages express the proportion of each genotypic category within each treatment arm or ethnic group SFA, saturated fatty acids
p values are from Student’s t test
a
Statistical comparison for all groups combined
b
p values are from Fisher’s exact test
c
N/A, not available because of insufficient data (cell size<15)
d
p values are from Wilcoxon’s test